TRT and Testicular Atrophy: Causes, Prevention, and Treatment

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Testicular atrophy, or shrinkage, is a common and expected side effect of Testosterone Replacement Therapy (TRT) due to the suppression of the Hypothalamic-Pituitary-Testicular Axis (HPTA). Exogenous testosterone halts the brain's signals to the testes, leading to reduced natural production and testicular size. This can be prevented or mitigated by co-administering Human Chorionic Gonadotropin (hCG) with TRT, which directly stimulates the testes, preserving their function and size, and often fer

The Inevitable Consequence: TRT and Testicular Atrophy

Testosterone Replacement Therapy (TRT) is a cornerstone treatment for men suffering from symptomatic hypogonadism, effectively restoring physiological testosterone levels and alleviating a myriad of symptoms. However, one of the most common and often concerning side effects of TRT is testicular atrophy, or the shrinkage of the testicles. This phenomenon is a direct and expected consequence of how exogenous testosterone interacts with the body's natural hormonal regulatory system.

Understanding the Cause: HPTA Suppression

The root cause of testicular atrophy on TRT lies in the suppression of the Hypothalamic-Pituitary-Testicular Axis (HPTA). This intricate feedback loop controls the body's natural testosterone production:

• The hypothalamus releases Gonadotropin-Releasing Hormone (GnRH).
• GnRH stimulates the pituitary gland to secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).
• LH signals the Leydig cells in the testes to produce testosterone, while FSH is crucial for spermatogenesis (sperm production) within the seminiferous tubules of the testes.

When exogenous testosterone is introduced via TRT, the brain (hypothalamus and pituitary) detects sufficient circulating testosterone. This triggers a negative feedback mechanism, signaling the hypothalamus to reduce GnRH release and the pituitary to drastically decrease its production of LH and FSH. Without these critical signals, the testes are no longer stimulated to produce their own testosterone or sperm. Consequently, the Leydig cells and seminiferous tubules, which constitute the bulk of testicular volume, become inactive and diminish in size, leading to atrophy.

Studies have consistently shown that testicular volume can decrease by approximately 10% to 30% within a few months of initiating TRT. This reduction in size is not only a cosmetic concern for some men but also directly correlates with impaired fertility, as sperm production is significantly reduced or halted.

Prevention: The Role of Human Chorionic Gonadotropin (hCG)

For men on TRT who are concerned about testicular atrophy or wish to preserve fertility, the co-administration of Human Chorionic Gonadotropin (hCG) is the primary and most effective preventive strategy. hCG is a hormone that structurally and functionally mimics LH. By introducing hCG, the Leydig cells in the testes are directly stimulated, bypassing the suppressed pituitary signals. This stimulation encourages the testes to continue producing their own testosterone and helps maintain their size and function, including some level of spermatogenesis.

Typical hCG protocols when used with TRT involve doses ranging from 250 IU to 1000 IU, administered subcutaneously 2 to 3 times per week. This approach helps to keep the testes active, preventing the significant shrinkage that would otherwise occur with TRT monotherapy. It is important to note that while hCG can mitigate atrophy and preserve some fertility, it does not guarantee full fertility for all men, and sperm parameters should be monitored if conception is a goal.

Treatment and Management of Existing Atrophy

If testicular atrophy has already occurred due to TRT and a man wishes to address it, several approaches can be considered:

• Initiating hCG: If hCG was not used initially, adding it to the TRT regimen can often reverse atrophy to a significant extent. The testes, once stimulated, can regain much of their original size and function.
• Discontinuation of TRT and PCT: For men who are willing to come off TRT, a Post-Cycle Therapy (PCT) protocol involving hCG and Selective Estrogen Receptor Modulators (SERMs) (e.g., Clomiphene or Enclomiphene) can be implemented. This aims to fully reactivate the natural HPTA, which will lead to the restoration of testicular size as endogenous testosterone and sperm production resume. However, this means discontinuing the benefits of TRT and enduring a period of potential hypogonadal symptoms.
• Testicular Prostheses: In rare cases where atrophy is severe, irreversible, and causes significant psychological distress, surgical implantation of testicular prostheses can be considered for cosmetic purposes. This does not restore function but addresses the aesthetic concern.

Conclusion

Testicular atrophy is a well-understood and common side effect of TRT, stemming from the suppression of the HPTA. While it is an expected physiological response, it is largely preventable and treatable. For men embarking on TRT, a thorough discussion with their healthcare provider about the risks and benefits, including the option of co-administering hCG, is essential. Proactive management allows men to enjoy the profound benefits of optimized testosterone levels while mitigating undesirable side effects and preserving aspects of their reproductive health.